CENTOCOR, INC.
🇺🇸United States
A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01081704
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT01008995
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
Phase 3
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2013-12-25
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 592
- Registration Number
- NCT00973479
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT00955279
A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis
Phase 1
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT00925574
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: CNTO 3649 SC (Healthy participants)Drug: CNTO 3649 IV (Healthy participants)Drug: CNTO 3649 SC (Diabetic patients)Drug: Placebo
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT00882726
A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2010-04-27
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00844909
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
Phase 1
Completed
- Conditions
- Head and Neck NeoplasmsLung NeoplasmsOvarian NeoplasmsPancreatic NeoplasmsColorectal Neoplasms
- Interventions
- Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT00841191
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Phase 2
Completed
- Conditions
- Pulmonary Fibrosis
- Interventions
- Drug: PlaceboDrug: CNTO 888 1 mg/kgDrug: CNTO 888 5 mg/kgDrug: CNTO 888 15 mg/kg
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT00786201
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
Phase 2
Completed
- Conditions
- Crohn's Disease
- Interventions
- Drug: Ustekinumab 3 mg/kg (IP)Drug: Ustekinumab 6 mg/kg (IP)Drug: Placebo (IP)Drug: Ustekinumab 1mg/kg (IP)Drug: Placebo IV - Responder - Placebo SC (MP)Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)Drug: Ustekinumab IV - Responder - Placebo SC (MP)Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP)Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2013-04-01
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 526
- Registration Number
- NCT00771667
© Copyright 2025. All Rights Reserved by MedPath